SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Micawber who wrote (624)8/14/2000 8:29:05 AM
From: dalroi  Respond to of 1475
 
updated version

PPL Therapeutics says "not involved" in pig organ research cut-off as shares fall
PPL Therapeutics (LSE: PTH.L - news) told FTMarketWatch it is "not involved" in a cut-off of research into using cloned pigs as organ donors for humans.
PPL shares fell almost 13% after published reports said research on pig transplants would be halted at Scotland's Roslin Institute, apparently due to concerns that pig viruses could be transfered to human donors.

PPL said its own separate research on pig organ transplantation would continue.

PPL announced in March it had succeeded in cloning pigs, and hopes to use genetic engineering to eliminate organ rejection.

Click here for more from FT MarketWatch



To: Micawber who wrote (624)8/14/2000 9:17:02 AM
From: scaram(o)uche  Read Replies (2) | Respond to of 1475
 
There are a few companies that may have beaten PPL to the prize. There are some companies that will have applications beyond the initial task of cloning. I guess that GERN/Roslin wasn't among them.

They could have said "we got scooped".

If you do an EPO search for "porcine retrovirus", you'll find two companies with applications..... Imutran and BTRN.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News